Ephedrin-Carinopharm 30 mg/ml Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ephedrin-carinopharm 30 mg/ml

carinopharm gmbh (8031371) - ephedrinhydrochlorid - konzentrat zur herstellung einer injektionslösung - teil 1 - konzentrat zur herstellung einer injektionslösung; ephedrinhydrochlorid (00120) 30 milligramm

Ephedrinhydrochlorid Aguettant 3 mg/ml Injektionslösung in Fertigspritze Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ephedrinhydrochlorid aguettant 3 mg/ml injektionslösung in fertigspritze

laboratoire aguettant (8026476) - ephedrinhydrochlorid - injektionslösung in einer fertigspritze - teil 1 - injektionslösung in einer fertigspritze; ephedrinhydrochlorid (00120) 30 milligramm

Ephedrin-hameln 30 mg/ml Injektionslösung Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ephedrin-hameln 30 mg/ml injektionslösung

hameln pharma gmbh (8084054) - ephedrinhydrochlorid - injektionslösung - teil 1 - injektionslösung; ephedrinhydrochlorid (00120) 30 milligramm

EPHEDRINE sulfate injection solution USA - engelsk - NLM (National Library of Medicine)

ephedrine sulfate injection solution

cantrell drug company - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 10 mg in 1 ml

PSEUDOEPHEDRINE HCL tablet, extended release USA - engelsk - NLM (National Library of Medicine)

pseudoephedrine hcl tablet, extended release

aurohealth llc - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - pseudoephedrine hydrochloride 120 mg - nasal decongestant - temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies - temporarily relieves sinus congestion and pressure if you are now taking a prescription monoamine oxidase inhibitor (maoi) (certain drugs for depression, psychiatric or emotional conditions, or parkinson’s disease), or for 2 weeks after stopping the maoi drug. if you do not know if your prescription drug contains an maoi, ask a doctor or pharmacist before taking this product. - heart disease - high blood pressure - thyroid disease - diabetes - trouble urinating due to an enlarged prostate gland -  nervousness, dizziness, or sleeplessness occur - symptoms do not improve within 7 days or occur with a fever

PSEUDOEPHEDRINE HYDROCHLORIDE tablet, film coated, extended release USA - engelsk - NLM (National Library of Medicine)

pseudoephedrine hydrochloride tablet, film coated, extended release

chain drug consortium, llc - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - pseudoephedrine hydrochloride 120 mg - nasal decongestant - temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies - temporarily relieves sinus congestion and pressure

EPHEDRINE SULFATE injection USA - engelsk - NLM (National Library of Medicine)

ephedrine sulfate injection

akorn - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations ]. animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these

EPHEDRINE SULFATE injection, solution USA - engelsk - NLM (National Library of Medicine)

ephedrine sulfate injection, solution

par pharmaceutical, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none r isk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations] . animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. c linical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. th

EPHEDRINE SULFATE injection USA - engelsk - NLM (National Library of Medicine)

ephedrine sulfate injection

akorn - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations ]. animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these